Carvolix secures new €10 million financing tranche
Carvolix secured a new €10 million financing tranche, bringing total financing under its €30 million programme to €20 million and supporting Tavipilot commercialization plus regulatory and clinical work.
Evidence notes
- The reserved offering issues 2,976,190 new ordinary shares at €3.36 per share to existing shareholders.
- Carvolix says proceeds support Tavipilot commercialization in the United States and development of Tavipilot, Kalios, Artus, Artedrone and Mitrapilot.
- The tranche extends the company’s cash runway to the end of September 2026, with venture debt under negotiation.